ENYO Pharma
- Biotech or pharma, therapeutic R&D
ENYO Pharma is a clinical-stage biopharma with extensive phase I/II clinical data (9 completed clinical studies; 300+ subjects) for Vonafexor and EYP651. ALPESTRIA-1, a Phase 2 study in Alport Syndrome will have data available from mid-year 2025. ADPKD preclinical data will be available at BIO. Clinical work with EYP651 to start this year can also be discussed.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}